1Globe Biomedical

PURSUING A POTENTIALLY TRANSFORMATIVE CANCER TREATMENT APPROACH

1Globe Biomedical is a clinical stage biotechnology company pioneering the development of receptor T (1BioCARs™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” receptor T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.

We BELIEVE

We believe the next revolution in cancer treatment is the development of receptor T therapies, or 1BioCARs™, which are engineered from the T cells of healthy donors. These off-the-shelf receptor T therapies enhanced by gene editing could be the next most important breakthrough in the field. Our mission is to catalyze this immune cell therapy approach and deliver 1BioCARs™ to patients with hematologic cancers and solid tumors to make a difference in their lives.

Our HISTORY

In December 2018, we completed a $250 million financing round, from a premier investment group that included the following financial institutions: Bank of China, HSBC and Mayflower Advisors.